Viewing StudyNCT04486833

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
View Study With Definitions
Ignite Creation Date: 2024-05-06 @ 2:59 PM
Last Modification Date: 2024-10-26 @ 1:41 PM
Study NCT ID: NCT04486833
Status: RECRUITING
Last Update Posted: 2024-06-26
First Post: 2020-07-22
Brief Title: Quaratusugene Ozeplasmid Reqorsa and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
Sponsor: Genprex Inc
Organization: Genprex Inc
Overview Dates Organization Conditions Design Enrollment Locations Outcomes

Conditions & Keywords Data

Conditions:
Name
Carcinoma Non-Small Cell Lung
Keywords:
Name View
quaratusugene ozeplasmid View
Epidermal growth factor receptor mutation EGFR View
osimertinib View
Tumor suppressor gene 2 TUSC2 View
Lipid nanoparticle LNP View
Gene therapy View
Tagrisso View
FUS1-nanoparticles View
NSCLC View
Reqorsa View